MOSCOW — Russia’s healthcare system is undergoing its most significant transformation in decades. While the state remains the dominant provider—accounting for 75% of all medical services by value—the private sector is growing at nearly twice the rate of the public system, and the government is pouring unprecedented resources into digitalization, pharmaceutical independence, and workforce expansion.
The State-Private Divide
In 2025, Russia’s medical services market reached 9.7 trillion rubles. State medicine accounted for 7.3 trillion rubles, or 75% of the total, while the commercial segment reached 2.4 trillion rubles—a quarter of the market. The private sector’s share has grown by six percentage points over the past five years, expanding at an average annual rate of nearly 16%, compared to 8.8% for state medicine.
The largest private players are Medsi (61.4 billion rubles in revenue), Mother and Child (43.5 billion), Medskan (32.6 billion), SM-Clinic (31.5 billion), and EMC (27.2 billion). Despite this growth, the market remains fragmented: the top 50 players accounted for only about 17% of the market in 2025, a figure expected to reach 22% by 2030.
Commercial medicine is projected to grow at an average of 12.8% annually, reaching 4.36 trillion rubles by 2030. Sovcombank analysts forecast the overall medical services market will hit 12.6 trillion rubles by 2028, with state medicine growing at 5% and private at 14%.
The Pharmaceutical Push
Russia’s pharmaceutical industry is approaching a symbolic milestone. In 2025, production of finished medicinal products reached 999 billion rubles—a 15.7% increase in ruble terms over 2024—with approximately 4.03 billion packages released into circulation. Manufacturers are shifting toward larger consumer packages, evidenced by a 2% decline in package numbers but a 2.5% increase in minimum dosage units.
Domestic drugs now account for 64.2% of the market in physical terms and 45.9% in value, according to the Ministry of Industry and Trade. The government’s import substitution drive has registered 55 of 185 targeted drugs and 65 of 379 medical devices that were previously imported.
Notable production trends include a 92% surge in Spironolactone output, driven by four domestic manufacturers, and significant growth in diabetes treatments such as Gliclazide, Forsiga, and Metformin, which rose between 46% and 82%. Among over-the-counter products, “Ant Alcohol” production tripled, likely reflecting off-label consumption as an alcohol substitute.
Medical Devices and Technological Sovereignty
The medical device market reached 850 billion rubles in 2024, growing 18% since 2021. Domestic products now hold approximately 30% of the market, up seven percentage points over five years. Rostec, the state corporation, operates 30 specialized enterprises in medical instrumentation with over 200 product types, reporting 52% growth in in-vitro diagnostics and 65% growth in rehabilitation equipment.
Roszdravnadzor head Alla Samoylova noted that the medical device market grew about 14% in 2024, with import substitution becoming a “strategic imperative” for technological sovereignty. The national project “New Technologies for Health Preservation,” launched in 2025, supports clinical trials of 23 new medical devices and 8 original drugs.
The Workforce Crisis
Perhaps the system’s most acute challenge is human capital. As of early 2025, Russia faced a shortage of 23,300 doctors and 63,600 mid-level medical personnel. In 54 regions, specialist availability falls below the national average. Two-thirds of doctors work more than one full-time equivalent, and district therapists serve an average of 2,800 patients against a norm of 1,700—65% above the standard.
The State Duma has responded with legislation establishing a formal mentorship system for new medical graduates. The law requires graduates to work under supervision for up to three years in organizations participating in the compulsory medical insurance system. It also introduces 100% targeted enrollment for residency programs and maintains 70% targeted quotas for specialist degrees.
Health Minister Mikhail Murashko reported that approximately 9,000 doctors entered the compulsory insurance system in 2025—a figure not seen before 2023. He attributed the improvement to programs like “Zemsky Doctor” and “Zemsky Feldsher,” which offer incentives for rural practice.
Digitalization and the New Healthcare Model
Russia’s healthcare system is being reshaped by digital transformation. The Unified State Information System now supports electronic medical records, online appointment scheduling, electronic sick leave, and digital prescriptions. From 2026, the state guarantees program includes a separate section for telemedicine, and the compulsory insurance program has been expanded to include remote monitoring for patients with hypertension or elevated blood sugar.
The government’s strategic vision, articulated in the Healthcare Development Strategy through 2030, emphasizes a shift “from reactive to predictive medicine.” Priority areas include medical decision support systems, artificial intelligence, remote patient monitoring, digital twins, and robotics.
A preventive focus remains central to the system’s design. The state guarantees program establishes six differentiated standards for preventive care, and since 2019, employees have the right to one paid day off every three years for medical examinations. Medical organizations are increasingly offering evening and weekend appointments to accommodate working citizens.
Outcomes and Challenges
There are signs of progress. Russia was removed from the World Health Organization’s list of countries with a high tuberculosis burden, and infant mortality has reached a historic low. The “Circle of Good” fund has assisted over 30,000 children with severe and rare diseases. High-tech medical care reached more than 1.7 million people in 2025, an 11% increase over 2024, and now includes innovative transplantation methods across 14 profiles.
Yet fundamental challenges persist. Life expectancy for Russian men—at approximately 64 years—remains the lowest in Europe, eleven years below the EU average, according to a Lancet report cited by Italian health publication Quotidiano Sanità. Cardiovascular diseases and violent causes, including alcohol poisoning and suicides, continue to drive excess mortality among working-age men.
The system’s trajectory is clear: consolidation of state provision, acceleration of private growth, aggressive import substitution, and digital modernization. Whether these efforts can overcome the structural workforce deficit and persistent health outcome gaps will determine the success of Russia’s healthcare transformation.
